Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Kolon Life Science to Export $207 Million of Gene Therapy Treatment to China's Hainan Province

publication date: Jul 20, 2018

South Korea’s Kolon Life Science signed a $207 million contract to export its osteoarthritis drug, Invossa-K, to China Life Medical Centre in Hainan Province. Invossa-K, the world’s first gene therapy treatment for osteoarthritis, was approved by Korea’s health authorities in July 2017. Hainan Province, an island off China's southwest coast, is China's center for medical tourism. The area can dispense drugs and use medical devices without the approval of China drug regulators. As part of the deal, China Life Medical will conduct clinical tests of Invossa-K for mainland China approval. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital